HAMF
ALXN

Hatteras Alternative Mutual Funds’s Alexion Pharmaceuticals ALXN Stock Holding History

Hatteras Alternative Mutual Funds’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-19,217
Closed -$2.92M – 217
2014
Q1 		$2.92M Buy
19,217
+14,517
+309% +$2.31M 1.4% 17
2013
Q4 		$625K Buy
+4,700
New +$564K 0.35% 103

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hatteras Alternative Mutual Funds's ALXN Position: Q2 2014 in Review

Hatteras Alternative Mutual Funds sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 19,217 shares — an estimated $2.92M sold.

Hatteras Alternative Mutual Funds first reported a position in ALXN in Q4 2013 and held it in 2 quarters. The position peaked at $2.92M in Q1 2014. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • Hatteras Alternative Mutual Funds reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Hatteras Alternative Mutual Funds sold 19,217 Alexion Pharmaceuticals shares in Q2 2014, an estimated $2.92M.
  • Hatteras Alternative Mutual Funds first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Hatteras Alternative Mutual Funds's Alexion Pharmaceuticals position peaked at $2.92M in Q1 2014.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on Hatteras Alternative Mutual Funds's 13F filing for Q2 2014, filed 13 Aug 2014.